Monday, 9 April 2012

Cytacon Tablets 50mcg





1. Name Of The Medicinal Product



Cytacon tablets


2. Qualitative And Quantitative Composition



Each tablet contains 50 micrograms Cyancobalamin BP.



3. Pharmaceutical Form



Tablet.



4. Clinical Particulars



4.1 Therapeutic Indications



Recommended Clinical Indications:



Treatment of nutritional Vitamin B12 deficiency.



Treatment of vitamin B 12 deficiency following partial gastrectomy.



Treatment of tropical sprue, alone or with folic acid.



Treatment of pernicious anaemia when parenteral administration is not possible or not advised.



4.2 Posology And Method Of Administration






Dosage:




Adults: - One to three tablets or more daily at the discretion of the physician. Alternatively, one or two 5ml spoonfuls of Cytacon liquid two or three daily, or more at the discretion of the physician. In pernicious anaemia, intramuscular therapy is preferable for initial correction of vitamin B 12 deficiency. The oral route may be follow this at dose of at least 300mcg daily.



Elderly: - As for adults. Alternatively, one or two 5ml spoonfuls of Cytacon liquid two or three daily, or more at the discretion of the physician.



Children: - One tablet daily at the discretion of the physician. Alternatively, one 5ml spoonful of Cytacon liquid two or three times daily, or more at the discretion of the physician.



When possible, Cytacon doses should be taken between meals.



Method of administration: Oral.



4.3 Contraindications



Hypersensitivity to the product or any of the excipients.



4.4 Special Warnings And Precautions For Use



For pernicious anaemia, an adequate dose must be used and the blood picture must be examined regularly at least every three months for 18 months until stabilised, and then annually.



Indiscriminate administration of Cytacon may mask precise diagnosis.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Absorption may be reduced by Para-aminosalicylic acid, colchinine, biguanides, neomycin, cholestyramine, potassium chloride, methyldopa, and cimetidine.



Patients treated with chloramphenicol may respond poorly to Cytacon.



Serum levels of Cyancobalamin may be lowered by oral contraceptives. These interactions are unlikely to have clinical significance.



Anti-metabolities and most antibiotics invalidate vitamins B12 assays by microbiological techniques.



4.6 Pregnancy And Lactation



Cytacon should not be used to treat megaloblastic anaemia of pregnancy because this is due to folate deficiency.



4.7 Effects On Ability To Drive And Use Machines



None.



4.8 Undesirable Effects



Sensitisation to cyancobalamin is rare, but may present as an itching exanthema, and exceptionally as anaphylactic shock.



Acneform and bullous eruptions have been reported rarely.



Patients who have become sensitised to cyanocobalamin by injection are often able to tolerate cyancobalamin by the oral route without trouble.



4.9 Overdose



Overdosage is unlikely to require treatment.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Cytacon tablets contain cyancobalamin vitamin B 12, which is used for the treatment of pernicious anaemia, and nutritional deficiencies of vitamin B 12 which results in macrocytic anaemia.



5.2 Pharmacokinetic Properties



The absorption of cobalamins from the gut is dependent upon the glycoprotein intrinsic factor. Cobalamins are transported rapidly into the blood bound to protein, known as transcobalamins. Cobalamins are stored in the liver and excreted in the bile. They are known to cross the placenta.



5.3 Preclinical Safety Data



No further relevant data.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Lactose BP



Maize Starch BP



Magnesium Stearate BP



Purified Water BP



Film coat



Hydroxypropyl Methylcellulose 2910 USP



Ethylcellulose



Acetylated Monoglyceride



Speedcolour White 27120 Ansteads HSE (Titanium dioxide, talc and polysorbate)



Isopropyl Alcohol BP



Dichloromethane BP



6.2 Incompatibilities



None stated.



6.3 Shelf Life



36 months in securitaners



24 months in blisters



6.4 Special Precautions For Storage



Securitainer



Protect from light.



Store in well closed containers.



Blisters



Store below 25°C, protected from light.



6.5 Nature And Contents Of Container



Polyproylene container with a tamper evident low density polyethylene lid, containing 50 or 100 Cytacon tablets.



Tampertainer staysafe made from high density polyethylene containing 50 or 100 tablets.



PVC/PVdC /Aluminium blister packs with 28, 56 or 112 tablets.



6.6 Special Precautions For Disposal And Other Handling



None



ADMINISTRATIVE DATA


7. Marketing Authorisation Holder



Goldshield Group Limited



NLA Tower



Croydon



Surrey



CR0 OXT



Trading as Golshield Pharmaceuticals.



8. Marketing Authorisation Number(S)



PL 10972/0028



9. Date Of First Authorisation/Renewal Of The Authorisation



16th November 1993



10. Date Of Revision Of The Text



11/09/2010




No comments:

Post a Comment